The Inflation Reduction Act stands as key legislation aimed at improving the accessibility of medicines, yet it has introduced some potential unintended consequences on biotechnology innovation and patients suffering from orphan diseases. In response, the Orphan Cures Act has emerged as a proposed bill dedicated to bolstering research and development for rare diseases. This webinar will explore how these legislative efforts intersect, examining their impact on the delicate balance between innovation, affordability, and access in the realm of rare disease treatments.

Speakers:

Mason Barrett, Policy Analyst, National Organization for Rare Disorders (NORD)

Jon Brodo, Policy Director, Todd Strategy

Cartier Esham, PhD, Chief Scientific Officer & EVP of Emerging Companies, Biotechnology Innovation Organization (BIO)

Moderator:

Erika Modina, MS, 2023-25 Policy Fellow, Stanford Byers Center for Biodesign